Nestle enters agreement to develop ulcerative colitis therapy

ZURICH (Reuters) - Nestle is working with Lipid Therapeutics to develop and commercialize a new therapeutic treatment for mild-to-moderate ulcerative colitis, which can causes ulcers, bleeding and pain due to inflammation of the colon, the company said on Wednesday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news